NCT02142920View on ClinicalTrials.gov

Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Healthy

Interventions

DRUG

PF-05212384

Single 89 mg Dose via 30 minute IV infusion

Trial Locations (1)

NG11 6JS

Pfizer Investigational Site, Ruddington Fields

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY